-
-
-
-
-
-
-
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
-
-
-
-
-
-
-
Oppenheimer on Gilead Sciences (GILD): 'Story Near-Term Remains Squarely HIV Focused'
-
-
-
-
-
-
-
Clear Street Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)
-
-
-
-
-
-
-
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
-
-
-
-
-
-
-
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
-
-
-
-
-
-
-
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
-
-
-
-
-
-
-
Gilead Sciences Announces Third Quarter 2025 Financial Results
-
1,154,895 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

